indiaUpdated: May 30, 2020 05:42 ISTUS pharma giant Gilead Sciences has applied to India’s drug regulator seeking marketing authorisation for its anti-viral drug remdesivir, which is being touted as a potential treatment for Covid-19. Gilead Sciences, who is the patent holder of the drug, has the complete data about the pre-clinical and clinical studies for remdesivir, sources said. Click here for full Covid-19 coverage“The company has applied seeking marketing authorisation for its anti-viral drug remdesivir to India’s Central Drugs Standard Control Organisation (CDSCO). This comes in the backdrop of two Indian pharmaceutical companies -- Cipla and Hetero Labs -- applying to the drug regulator seeking permission to manufacture and sell remdesivir in India. They have also sought a clinical trial waiver for remdesivir so that the medicine can be made available for the patients faster, an official said.

Source: Hindustan Times May 30, 2020 00:13 UTC